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ABSTRACT (246 of 250 words allowed) 
Purpose: To investigate whether effectiveness of an osteoporosis screening programme to reduce hip fractures 
was mediated by modification of falls risk in the screening arm. 
Methods: The SCOOP study recruited 12,483 women aged 70-85 years, individually randomised to a control 
(n=6,250) or screening (n=6,233) arm; in the latter, osteoporosis treatment was recommended to women at high 
risk of hip fracture, while the control arm received usual care.  Falls were captured by self-reported questionnaire.  
We determined the influence of baseline risk factors on future falls, and then examined for differences in falls risk 
between the randomisation groups, particularly in those at high fracture risk.  
Result:  Women sustaining one or more falls were slightly older at baseline than those remaining falls free during 
follow up (mean difference 0.70 years, 95%CI 0.55-0.85, p<0.001).  A higher FRAX 10-year probability of hip 
fracture was associated with increased likelihood of falling, with fall risk increasing by 1-2% for every 1% 
increase in hip fracture probability.  However, falls risk factors were well balanced between the study arms and, 
importantly, there was no evidence of a difference in falls occurrence.  In particular, there was no evidence of 
interaction (p=0.18) between baseline FRAX hip fracture probabilities and falls risk in the two arms, consistent 
with no impact of screening on falls in women informed to be at high risk of hip fracture.  
Conclusion: Effectiveness of screening for high FRAX hip fracture probability to reduce hip fracture risk was 
not mediated by a reduction in falls. 
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Mini abstract (45 of 50 words allowed) 
A reduction in hip fracture incidence following population screening might reflect the effectiveness of 
anti-osteoporosis therapy, behaviour change to reduce falls, or both.  This post hoc analysis demonstrates that 




In 2010, in the EU, there were 610,000 hip fractures with their management alone accounting for €25bn 
of expenditure [1]. Of many factors that influence the risk of hip fracture, age-related reductions in bone mass and 
increased likelihood of falling are long recognised to be important contributors [2].  While assessment of falls risk 
and appropriate interventions aimed at reducing falls risk have been shown to be effective [3], at least in the short 
term, their impact on the risk of hip fracture is less certain.  For example, in a recent review undertaken for the 
US Preventive Services Task Force, multifactorial interventions or single exercise-based interventions were found 
to reduce falls risk, but the impact on fractures was not significant [4].  In contrast, several randomised, placebo-
controlled trials have shown that treatments directed at preventing bone loss and/or improving bone mass can 
reduce the incidence of hip fracture by 30-45% [5-7].   
Recently, the UK based SCOOP study investigated whether community-based screening, using a FRAX 
assessment of 10-year hip fracture probability, could reduce the incidence of fractures by targeting osteoporosis 
treatment to women at high risk of hip fracture [8].  This large study with 5 years of follow up found that the 
screening programme led to a 28% reduction in hip fractures.  A subsequent analysis confirmed that the risk 
reduction was predominantly observed in those deemed to be at high risk of fractures [8, 9], suggesting the effect 
was mediated by appropriately targeted osteoporosis medication.  An alternative hypothesis might be that 
screening itself, and/or the knowledge of being at high risk, coupled with the patient’s perception of linkage 
between falls and fractures, could have altered behaviour related to falls risk.  Evidence exists that screening can 
encourage those screened to improve their health behaviour [10], and that screening participants are more likely 
to follow health-related feedback and alter their lifestyle than those who do not participate [11, 12].  In contrast, 
screening can have a ‘certificate of health’ effect whereby a negative screening result gives patients reassurance 
which makes them more resistant to health recommendations in the future as they believe that their current 
lifestyle is adequate and have a lower perceived threat of disease [10, 11, 13]. 
Given these potential impacts of screening on lifestyle factors, there is uncertainty as to whether 
screening for osteoporosis might influence falls occurrence or behaviour.  This post hoc analysis of the SCOOP 
trial aimed to answer this by identifying risk factors for falling, comparing their distribution in the screening and 
control arms and, finally determining whether falls were reduced in the screening arm, particularly in women 




The SCOOP study, a 5-year randomised controlled trial of the impact of screening for high hip fracture 
risk on fracture incidence, has been described in detail elsewhere [8, 14].  Briefly, it recruited 12,483 women aged 
between 70-85 years, untreated for osteoporosis, from 100 GP practices in 7 regions across England.   
Baseline data and randomisation 
At study entry, clinical risk factors were collected directly from participants by postal questionnaire to 
assess fracture probability by FRAX.  Variables included age, height and weight (to calculate BMI), as well as 
prior fracture (since the age of 50 years), parental hip fracture, glucocorticoid use, rheumatoid arthritis, smoking 
and alcohol exposure.  Self-reported causes of secondary osteoporosis, including insulin dependent diabetes, 
Crohn’s disease, thyroid overactivity, early menopause, organ transplantation and poor mobility were collected, 
as well as the number of self-reported falls in the previous 12 months [14].  Participants were then randomised 
into the two arms of the study, the screening arm or ‘usual care’ control arm. 
Screening and control arms 
In the screening arm, the FRAX tool was used to calculate participants’ 10-year probability of hip 
fracture, with those deemed at moderate to high risk of hip fracture invited for a dual-energy x-ray 
absorptiometry (DXA) measurement of femoral neck bone mineral density (BMD); the 10-year hip fracture 
probability was then recalculated with inclusion of BMD.  The final risk category (low or high) was 
communicated to the participant and family doctor with those at high risk advised to discuss treatment options.  
Whether at low or high risk, the GP was also asked to advise about the need to increase exposure to weight-
bearing exercise, to stop smoking and to decrease alcohol intake, where appropriate.  In the control arm, apart 
from communications to the GP and participant about their inclusion in the study, they received usual care 
from their GP and did not receive information about fracture risk.   
Prior falls and incident falls 
Falls in the previous 12 months were captured at study entry and self-reports of subsequent falls were 
captured by postal questionnaire at 6, 12, 24, 36, 48 and 60 months post randomisation, where patients reported 
falls occurring since the previous questionnaire completion.  Prior or subsequent reported falls were not validated 
from other independent sources during follow up.  A fall was defined as a sudden, unintentional coming to rest 
on the ground, floor, or other lower level [15].   
Statistical analysis 
Differences in baseline characteristics, including clinical risks for FRAX calculation, between those 
women with or without a fall in the year prior to entry were compared using relevant descriptive statistics.   
The proportion of women remaining fall-free was estimated with the Kaplan-Meier method.[16]  Cox 
regression was used to examine the relationships between incident falls and baseline risk factors as well as the 
assigned study arm, with and without adjustment for predictors of falls.  Any participant self-reporting one or 
more falls during follow-up was classified as a faller.  Sensitivity analyses using faller definitions of those 
experiencing at least 5 falls (i.e. on average 1 or more falls per year during the 5 years of the study) and those 
experiencing at least 10 falls (i.e. on average 2 or more falls per year during the 5 years of the study) were also 
conducted. 
An extension of Poisson regression model was used to study the relationship between age, the time 
since baseline, study arm (screening or usual care), and FRAX 10-year probability of hip fracture on the one 
hand and on the other hand, the time to first fall for base case, and time to 5th or 10th fall for sensitivity analyses.  
As BMD measurements were not undertaken in all participants, the baseline 10-year FRAX probabilities, 
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without the inclusion of BMD, were utilised for these analyses.  The variable “10-year probability screening” 
tested for an interaction between screening effectiveness and baseline 10-year probability, handled as a 
continuous variable.  No reduction in falls risk and a lack of interaction, with a flat relationship across the range 
of baseline risk, would suggest that screening had no impact on falls risk to mediate the observed reduction in 
hip fractures.  A similar approach was used to investigate an interaction between hip fracture probability and 
reduced fracture risk in the screening arm compared to the control arm [9]. 
All analyses were conducted on an intention-to-treat basis with participants analysed according to the 
group to which they were randomised, irrespective of whether screening was completed.  Hazard ratios (HR) for 
screening effect and 95% confidence intervals (95% CI) were computed for risk of falls as a continuous 
variable.  For presentation, hazard ratios are shown at the 10th, 25th, 50th, 75th, and 90th percentile of fracture 





The baseline characteristics of the participants in each study arm are shown in Table 1. There were no 
appreciable differences between the two arms of the study; importantly, the prevalence of falls in the year prior 
to study entry was very similar in both arms whether this was analysed as any reported fall or a history of 2 or 
more falls (i.e. multiple previous falls) (Table 1). Within the screening arm, the prevalence of multiple previous 
falls was slightly but not significantly higher (14.9%) in those identified at high future risk of hip fracture by 
FRAX probability than in the rest of the screening group (13.1%, p=0.16). 
 
Women with a history of one or more falls in the previous year were slightly older, with a higher mean 
BMI, and higher prevalence of FRAX risk factors apart from smoking (Table 2).  
 
Incident falls 
During the follow-up period providing 59,401 person-years of observation (mean 4.75 years per 
participant), there were 24,540 incident falls reported, with 6,760 (54.2%) of women reporting at least one fall.  
The proportion of women sustaining a new fall was similar in the control arm (3,332 of 6,250, 53.3%) and the 
screening arm (3,428 of 6,233, 55.0%).  Within those reporting incident falls, the total number of falls reported in 
any individual ranged from 1 to 314, with the majority (4,743, 70.2%) reporting 3 falls or fewer (Table 3).   
 
Those women who sustained one or more incident falls were slightly older at baseline (mean 75.8 years) 
than those remaining fall free during follow up (mean 75.1 years) (mean difference 0.70 years, 95%CI 0.55-0.85, 
p<0.001).  A number of other baseline characteristics were associated with the incidence of subsequent falls, 
largely independent of the number of incident falls used to classify an individual as a faller or not (Table 4).  Thus, 
a higher BMI, a history of prior fracture, glucocorticoid use, secondary osteoporosis, and fall or the number of 
falls in the year prior to entry were consistently associated with an increased risk of falling across the different 
classifications of fallers.  In addition, a higher FRAX 10-year probability of hip fracture was also consistently 
associated with higher subsequent risk of falling with fall risk increasing by 1-2% for every 1% increase in hip 
fracture probability (Table 4).  Importantly, there was no evidence that assignment to the screening arm had an 
impact on the future incidence of falls (Table 4 and Fig 1).  Fall-free survival, whether this was defined as free 
from any fall (Fig 1a) or, at the other extreme, free from at least 10 falls (Fig 1b) was very similar in the screening 
and control arms.  
 
Interaction between hip fracture probability, screening and falls risk 
The relationship between the hazard ratio for any incident fall in the screening arm compared to that in 
the control arm, across the range of baseline FRAX 10-year hip fracture probabilities, is shown in Fig 2.  There 
was no evidence of an interaction (p=0.18) with no difference in falls risk between the screening and control 
arms across the full range of baseline hip fracture probability.  The results were also similar by number of 
incident falls (Online resource 1).  Confidence intervals for the hazard ratio crossed unity at all probabilities for 




This analysis was designed to explore whether the reduction in hip fractures seen in the SCOOP study 
might have been mediated by a change in behaviour and decreased falls risk in the screening arm, particularly in 
those identified at high risk.  The results show no impact of screening on the incidence of falls, however defined, 
and this was true across the full range of baseline fracture risk.  This result complements a similar analysis which 
showed an interaction between screening and the reduction in hip fractures in those at higher risk in SCOOP.  
Together, these analyses are consistent with the effect of targeting of osteoporosis medications to such 
individuals[9], rather than a reduction in the frequency of falls.  
Our analysis identified a number of clinical risk factors associated with a future risk of falling, consistent 
with existing literature [17-26], including a history of one or more falls in the previous year, a prior fracture and 
self-reported poor mobility.  All three factors also showed a strong relationship with the occurrence of multiple 
falls.  Interestingly, we found that FRAX hip fracture probability, calculated without input of BMD, was also 
predictive of future falls across all definitions of future fallers.  In a study of elderly men included in the MrOS 
Sweden cohort, the risk of incident falls also increased with increasing FRAX probabilities at baseline[27], and 
our analysis suggests that this finding also applies to women.  
That the reduction in hip fractures seen in SCOOP is not mediated by a change in behaviours impacting 
on falls risk is an important finding.  While there is evidence from previous studies in other disease areas that 
screening can exert positive or negative influences on health behaviour [10-13], it is clear that screening for high 
fracture risk had no impact on falls occurrence in SCOOP.  That falls risk is an important contributor to incident 
hip and non-vertebral fractures is both logical and demonstrable [28-32]; however, the SCOOP study 
demonstrates that the incidence of hip fracture can be reduced by treatments that target osteoporosis rather than 
falls risk.  These data are in keeping with a large body of evidence from randomised, placebo-controlled clinical 
trials of predominantly anti-resorptive treatments in osteoporosis [6, 33-35].  Of note, a similar, if smaller, 
reduction in hip fracture has also been reported in the ROSE screening study in Denmark using a slightly 
different FRAX-based strategy [36], suggesting that FRAX-based targeting of osteoporosis treatments might 
play a significant role in decreasing the burden of hip fractures.  That the efficacy of intervention is mediated 
predominantly by changes in BMD is supported by the comparative effects of the intervention on hip fracture 
and osteoporotic fracture.  For the prediction of hip fracture, risk decreases 2.6-fold for each standard deviation 
increase in femoral neck BMD, whereas the decrease in risk for any osteoporotic fracture is in the order of 1.5 
fold[37].  Given that the hip fracture rate decreased by 28%, the expected effect on osteoporotic fractures would 
be a hazard ratio of 0.87;  this hazard ratio lies within the 95% confidence intervals of the effect reported in 
SCOOP for osteoporotic fractures (0·85–1·03).[8]   In contrast, uncertainty remains about the effectiveness and 
cost-effectiveness of falls prevention strategies to reduce hip fracture risk, compared, for example, to the 
targeted use of generic pharmacological interventions such as those used in SCOOP [4, 38-40].  This does not 
mean that falls prevention measures should not be included in patient management, but it does raise serious 
questions about the wisdom of calls for anti-osteoporosis medications for the prevention of hip fractures to be 
abandoned in favour of falls prevention focused strategies [41, 42].  
 Our study has a number of strengths and limitations.  One of the strengths of this analysis was that it 
was undertaken within the context of a well conducted, large, randomised, controlled clinical trial with a high 
incidence of the outcome of interest (falls).  Falls were not the primary outcome of SCOOP, however, and past 
falls and incident falls were captured by unverified self-report only, most commonly at one-year intervals by 
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questionnaire.  Self-recall is associated with lower sensitivity (under-reporting of falls) but a high specificity 
[43].  This recall can be influenced in studies of interventions that target falls prevention, but this was not the 
case in SCOOP and there is no reason to believe that any recall bias was unequally distributed between the 
screening and control arms.  Additionally, the findings were robust across a series of definitions of fallers.  
Furthermore, the finding of well-established relationships between known risk factors and incident falls, 
however categorised, not only gives credence to the reporting of falls, but also further validates the accuracy of 
the observed lack of impact of screening on falls risk. 
Conclusion 
The SCOOP study, which targeted osteoporosis treatment to women at high risk of hip fracture, 
resulted in a lower incidence of hip fracture.  The present analysis demonstrates that this reduction in hip 
fractures was not mediated by a reduction in falls risk.   The additional benefits, if any, of combining effective 
osteoporosis treatments with approaches aimed at addressing falls risk should ideally be determined from well-
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Figure and Table Legend 
Fig. 1  Fall-free survival estimated by Kaplan-Meier analysis for the outcomes of a) any fall (i.e. one or more) 
and b) multiple falls defined as 10 falls or more.  There were no statistically significant differences between 
screening and control groups.  NB Note differences in the y-axis scales between the figures. 
 
Fig. 2  Impact of screening on falls risk (defined as one fall or more during follow-up) compared to the control 
arm, expressed as hazard ratio, across range of FRAX 10-year hip fracture probabilities at baseline, calculated 
without BMD.  
 
Table 1 Baseline characteristics of women assigned to the control and screening arms of the SCOOP study. 
 
Table 2 Characteristics of women reporting at least one fall compared to those with no falls in the year prior to 
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Fig. 1 – Fall-free survival estimated by Kaplan-Meier analysis for the outcomes of a) any fall (i.e. one or more) 
and b) multiple falls defined as 10 falls or more.  There were no statistically significant differences between 





Fig. 2  Impact of screening on falls risk (defined as one fall or more during follow-up) compared to the control 
arm, expressed as hazard ratio, across the range of FRAX 10-year hip fracture probabilities at baseline, 




Table 1 Baseline characteristics of women assigned to the control and screening arms of the SCOOP study. 




Age, years 75.5 (4.1) 75.4 (4.2) 
Height, cm 160.7 (6.3) 160.9 (6.4) 
Weight, kg 68.9 (12.7) 69.1 (12.7) 
BMI, kg/m2 26.7 (4.8) 26.7 (4.7) 
Self-reported prevalence (n, %) of:   
Fracture since age 50 years 1463 (23.4) 1399 (22.4) 
Parental hip fracture 577 (9.2) 585 (9.4) 
Current smoking 290 (4.6) 290 (4.7) 
Alcohol ≥3 units/day 225 (3.6) 219 (3.5) 
Glucocorticoid Use 312 (5.0) 316 (5.1) 
Rheumatoid Arthritis 410 (6.6) 426 (6.8) 
Secondary Causes of OP 1408 (22.5) 1483 (23.8) 
Falls in previous 12 months: 
Yes (≥1 fall) 










Table 2 Characteristics of women reporting at least one fall compared to those with no falls in the year prior to 
study entry.  





Age, years 75.4 (4.1) 76 (4.3) <0.001 
BMI, kg/m2 26.5 (6.3) 27.1 (5.0) <0.001 
Prior fracture (%) 1812 (20.3) 1021 (29.6) <0.001 
Parental hip fracture (%) 804  (9.0) 348 (10.1) 0.007 
Current smoking (%) 420 (4.7) 152 (4.4) 0.489 
Alcohol ≥3 units/day (%) 298 (3.3) 141 (4.1) 0.049 
Glucocorticoid use (%) 421 (4.7) 203 (5.9) 0.003 
Rheumatoid arthritis (%) 538 (6.0) 284 (8.2) <0.001 
Secondary osteoporosis (%)* 1879 (21.1) 979 (28.4) <0.001 
• Insulin-dependent diabetes 
mellitus (%) 157 (1.8) 91 (2.6) 0.015 
• Crohn’s disease (%) 136 (1.5) 66 (1.9) <0.001 
• Overactive thyroid (%) 443 (5.0) 199 (5.8) 0.041 
• Early menopause (%) 943 (10.6) 462 (13.4) <0.001 
• Organ transplant (%) 32 (0.4) 17 (0.5) 0.581 




Table 3 Table showing the number of incident falls reported by individual participants who fell at least once 
during follow up in the SCOOP study. 




1 2469 (36.5) 
2 1437 (21.3) 
3 837 (12.4) 
4 532 (7.9) 
5 or more 1485 (22.0) 




Table 4 Association between baseline variables and future falls risk, stratified by number of incident falls.  
Numbers represent the hazard ratio (HR) and 95%CI for the presence of the factor, other than for continuous 
variables where the HR relates to a unit increase in the variable, adjusted for age and time since baseline.  
Numbers in bold represent HRs with a CI that excludes the null. 
 
 Incident falls 
 ≥1 fall ≥5 falls ≥10 falls 
BMI (1kg/m2 increase) 1.01 (1.01, 1.02) 1.04 (1.03, 1.05) 1.07 (1.05, 1.09) 
Prior fracture 1.21 (1.15, 1.28) 1.35 (1.20, 1.51) 1.54 (1.24, 1.91) 
Parental hip fracture 1.19 (1.09, 1.29) 1.13 (0.94, 1.34) 0.97 (0.68, 1.39) 
Current smoking 0.92 (0.81, 1.04) 1.13 (0.87, 1.46) 1.55 (1.01, 2.38) 
Alcohol ≥3 units/day 1.03 (0.91, 1.17) 1.10 (0.84, 1.44) 0.74 (0.40, 1.40) 
Glucocorticoid use 1.24 (1.12, 1.38) 1.55 (1.26, 1.90) 1.65 (1.13, 2.42) 
Rheumatoid arthritis 1.16 (1.05, 1.27) 1.50 (1.24, 1.80) 1.34 (0.93, 1.93) 
Secondary osteoporosis 1.31 (1.24, 1.38) 1.76 (1.58, 1.97) 2.80 (2.29, 3.42) 
• Insulin-dependent 
diabetes mellitus 
1.22 (1.03, 1.45) 1.71 (1.25, 2.34) 2.88 (1.79, 4.62) 
• Crohn’s disease 1.15 (0.96, 1.39) 1.45 (1.01, 2.07) 1.67 (0.89, 3.12) 
• Overactive thyroid 1.07 (0.96, 1.19) 1.24 (0.99, 1.54) 1.74 (1.20, 2.51) 
• Early menopause 1.20 (1.12, 1.29) 1.31 (1.13, 1.53) 1.45 (1.10, 1.92) 
• Organ transplant 1.51 (1.06, 2.15) 1.88 (0.98, 3.62) 2.98 (1.11, 7.98) 
• Poor mobility 1.75 (1.59, 1.92) 3.35 (2.88, 3.89) 6.20 (4.90, 7.83) 
Fall in previous year (≥1 fall, yes 
or no) 
2.03 (1.93, 2.14) 3.84 (3.46, 4.27) 6.38 (5.13, 7.94) 
Fall in previous year (increase 
per reported fall)  
1.10 (1.09, 1.11) 1.14 (1.13, 1.15) 1.15 (1.14, 1.16) 
FRAX 10y hip probability (1% 
increase) 
1.01 (1.01, 1.01) 1.01 (1.01, 1.02) 1.02 (1.00, 1.03) 








Online resource 2– Further analysis for evaluate an impact of antiosteoporosis treatment to falls risk per 
screening or control group 
 
  ≥1 fall ≥5 falls ≥10 falls 
Anti-osteoporosis treatment    
• Within 5 months Control 1.20 (0.96, 1.49) 1.08 (0.67, 1.74) 1.15 (0.47, 2.80) 
Screening 1.12 (1.01, 1.23) 0.96 (0.77, 1.20) 0.90 (0.58, 1.40) 
• Within 1 years Control 1.34 (1.12, 1.55) 1.30 (0.93, 1.81) 1.83 (1.07, 3.16) 
Screening 1.19 (1.09, 1.31) 1.09 (0.89, 1.33) 1.14 (0.77, 1.67) 
• At sometimes 
during follow up 
Control 1.58 (1.45, 1.72) 1.51 (1.26, 1.80) 1.97 (1.43, 2.70) 
Screening 1.33 (1.23, 1.44) 1.24 (1.05, 1.47) 1.25 (0.91, 1.72) 
 
